The results of this study highlight a novel role for wild-type Ras signaling in cancer cells harboring oncogenic RAS mutations. Further, these findings reveal that therapeutically targeting oncogenic Ras signaling alone may be ineffective due to feedback activation of RTKs, and suggest that blocking upstream RTKs in combination with downstream effector pathways may be beneficial in the treatment of Ras mutant tumors.
INTRODUCTION
H-Ras, K-Ras, and N-Ras are founding members of the Ras family of small GTPases, and regulate cell growth, differentiation, and survival (1, 2) . Ras GTPases function as binary molecular switches, cycling between inactive GDP-bound and active GTP-bound states. In the basal state, Ras is predominantly GDP-bound. Activated RTKs recruit guanine nucleotide exchange factors (GEFs) to promote the exchange of bound GDP for GTP on nearby Ras molecules. In its GTP-bound state, Ras interacts with downstream effectors to activate signaling pathways important for cell growth and survival, including the mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) pathways (3, 4) . GTPase activating proteins (GAPs) facilitate the hydrolysis of bound GTP to GDP, returning Ras to its basal, inactive conformation and terminating downstream signaling. Ras therefore acts as a sensor of extracellular growth cues to ensure that signaling output through downstream effector pathways are of the appropriate intensity and duration.
The aberrant hyperactivation of Ras plays a causal role in human cancer, and an estimated 30% of human tumors harbor oncogenic somatic mutations in HRAS, KRAS or NRAS (5, 6) .
Oncogenic RAS alleles differ from their wild-type counterpart by a single missense point mutation that results in an amino acid substitution typically at position 12, 13, or 61 (6, 7) . These substitutions impair the rate of GAP-mediated GTP hydrolysis and consequently deregulate Ras signaling (5) (6) (7) . Oncogenic mutation in any one of the three RAS genes is thought to be sufficient to constitutively activate downstream signaling and confer independence from upstream growth cues (8) . Although the remaining two wild-type Ras isoforms remain subject to regulation by Young, et al. 5 GAPs and GEFs, the signaling contribution of the wild-type Ras isoforms in this context has been largely unexamined.
There are currently no curative therapeutic treatments for Ras mutant cancers (9) . Efforts to develop drugs that specifically block the activity of oncogenic Ras have been unsuccessful, although this remains an active area of investigation (10, 11) . Clinical studies demonstrate that oncogenic KRAS mutations predict resistance to EGFR inhibitors, hence the use of RTK inhibitors in this subset of cancers is usually contraindicated (12) . Developing drugs that inhibit signaling pathways downstream of Ras has thus been a key focus of clinical development. Smallmolecule compounds targeting the MAPK and PI3K effector pathways are currently under clinical investigation, as these pathways have been well-characterized and shown to be critical in mediating Ras-driven tumorigenesis (9, 13, 14) . However, the response to MEK kinase inhibitors varies across Ras mutant tumors, and clinical efficacy is thought to be limited by feedback activation of the PI3K pathway (14) (15) (16) (17) . Furthermore, Raf kinase inhibitors paradoxically activate MAPK signaling in cells harboring oncogenic RAS mutations, thereby precluding the use of these inhibitors in the treatment of Ras mutant cancers (18) (19) (20) . These findings highlight the complexity of effector pathway regulation and feedback mechanisms downstream of oncogenic Ras. Continued investigation of these signaling processes will be required to design effective targeted therapeutics.
In this study, we examine the regulation of MAPK and PI3K signaling in cancer cells with oncogenic RAS mutations. We utilize three cancer cell models, each of which harbors a homozygous RAS mutation: the T24 bladder cancer cell line (HRAS G12V), the MIA PaCa-2 pancreatic cancer cell line (KRAS G12C), and the RD rhabdomyosarcoma cell line (NRAS Q61H)
Research. activate downstream signaling, but that heightened activity can be achieved through activation of wild-type Ras isoforms by RTKs.
Wild-type Ras regulates growth factor signaling
To directly test the requirement for wild-type Ras in growth factor signaling, cells were transfected with siRNA to deplete the expression of the two wild-type RAS isoforms. The cells were then serum-starved overnight and signaling was measured before and after acute stimulation with EGF ( Figure 1B Figures 1B, 1C) . The increase in signaling correlates with enhanced GTP-loading on the wild-type Ras isoforms (Figures S1A, S1B), again highlighting a critical role for wild-type Ras in mediating growth factor signaling and suggesting that oncogenic Ras negatively regulates EGFR signaling, as we will discuss below.
We next examined whether effector pathway signaling could be suppressed by blocking RTK- signaling upon stimulation with its ligand ephrin-A1 (21, 22) . We thus utilized ephrin-A1 to block wild-type Ras activation. Ephrin-A1 attenuates EGF-induced activation of MAPK signaling and coincides with reduced GTP-loading on wild-type Ras isoforms ( Figure S3A ).
Importantly, wild-type Ras isoforms are required to mediate this effect, given that ephrin-A1 has no effect on ERK signaling in RD cells depleted of wild-type Ras compared to a robust suppression of ERK signaling when the oncogenic N-Ras isoform is depleted ( Figures S3B,   S3C ). Taken together, these data demonstrate that effector pathway signaling can still be modulated through wild-type Ras even in the presence of an oncogenic Ras isoform.
Oncogenic Ras regulates basal MAPK signaling
Depletion of oncogenic Ras results in a subtle yet reproducible reduction in the basal levels of ERK phosphorylation in serum-starved cells ( Figures 1B, 1D ) and in cells asynchronously growing in media supplemented with 10% serum (Figures 2A, 2B prevents this increase in basal ERK phosphorylation, suggesting that the increased ERK phosphorylation observed under conditions of wild-type Ras depletion is indeed driven by oncogenic Ras (data not shown). These data are consistent with a model in which the wild-type Ras isoforms antagonize basal oncogenic Ras signaling to the MAPK pathway.
Wild-type and oncogenic Ras differentially regulate cell proliferation
The results discussed above highlight unique roles for wild-type and oncogenic Ras in the that the differential regulation of basal MAPK signaling by wild-type and oncogenic Ras translate into independent and non-redundant roles in the regulation of cell growth, and that both are required to maintain optimal growth rates.
Oncogenic Ras negatively regulates EGFR sensitivity
As mentioned above, silencing oncogenic Ras expression sensitizes cells to EGF stimulation 
Combining oncogenic Ras depletion with EGFR inhibition enhances cell death
Although several small-molecule compounds targeting MEK are currently under clinical investigation, efficacy may be limited by feedback activation of EGFR-PI3K signaling (14) (15) (16) (17) .
Similarly, recent studies demonstrate that colorectal cancer cells harboring BRAF V600E mutations are unresponsive to the small-molecule RAF inhibitor PLX4032 (vemurafenib) due to feedback activation of EGFR, and that combining RAF and EGFR inhibition improves efficacy (33, 34) . Our results indicate that feedback activation of EGFR may also be a mechanism of resistance to therapies targeting either oncogenic Ras or oncogenic Ras-driven MAPK signaling.
We hypothesized that combining oncogenic Ras depletion with EGFR inhibition would block 
Young, et al. 13 survival Akt signaling through other RTKs (Figures 5, S5) . Thus, dual targeting of oncogenic Ras signaling and the appropriate RTK may be beneficial in the treatment of Ras mutant tumors.
DISCUSSION
The work presented here defines distinct roles for oncogenic and wild-type Ras in regulating effector pathway signaling in cancer cells harboring oncogenic RAS mutations. We show that oncogenic Ras regulates basal signaling and uncover an unexpected role for wild-type Ras in regulating growth factor signaling. Although oncogenic Ras constitutively activates MAPK signaling, acute activation of growth factor receptors can enhance this signaling by stimulating GTP-loading on wild-type Ras (Figure 7 ). Given that we detect this phenomenon in cell lines harboring oncogenic mutations in HRAS, KRAS, or NRAS, we conclude that these are not isoform-specific effects, but rather can be generalized to oncogenic and wild-type isoforms as a class. Collectively, these findings uncover an underappreciated role for wild-type Ras signaling in the context of oncogenic RAS mutations. Intriguingly, we found that depletion of wild-type Ras increases basal ERK phosphorylation, suggesting that wild-type Ras antagonizes oncogenic Ras signaling. The mechanism by which this antagonism occurs is not fully understood. In the basal state, wild-type Ras is predominantly GDP-bound. It is plausible that GDP-bound wild-type Ras inhibits oncogenic Ras signaling by sustaining unique and independent growth-inhibitory signaling pathways. Alternatively, different Ras isoforms might compete for common regulators, effectors or proper localization.
Prior studies indicate that wild-type Ras can antagonize the transforming potential of its
Research. (35) (36) (37) . While these data support a tumor suppressive role for the wildtype counterpart of the same oncogenic Ras isoform, our studies uncover a novel role for the remaining two wild-type Ras isoforms in antagonizing oncogenic Ras signaling.
It is unclear whether the specific inhibition of wild-type Ras activity, rather than the outright depletion of wild-type Ras expression, would similarly antagonize oncogenic Ras signaling.
Early studies on Ras signaling demonstrate that membrane-targeted p120 RasGAP antagonizes the transforming potential of oncogenic Ras in NIH3T3 cells, and that this antagonism is dependent on the catalytic activity of p120 RasGAP (38, 39) . One interpretation of these results is that transformation depends on additive signals from both oncogenic and wild-type Ras, and that the constitutive down-regulation of wild-type Ras activity by membrane-targeted p120
RasGAP is sufficient to inhibit transformation by oncogenic Ras. Another interpretation is that wild-type Ras, in a GDP-bound form, directly antagonizes oncogenic Ras signaling.
Alternatively, a combination of these mechanisms might be at play.
EphA2 negatively regulates Ras/MAPK signaling, and its expression is induced by high MAPK pathway activity (21, 22) . Remarkably, we show that blocking wild-type Ras activation by stimulating EphA2 with its ligand ephrin-A1 attenuates the EGF-induced activation of downstream signaling in cancer cells harboring oncogenic RAS mutations (Figures S3, 7) .
EphA2 knockout mice are significantly more susceptible to chemically-induced skin carcinogenesis driven by an activating mutation in Hras, demonstrating that EphA2 can exert tumor suppressive effects despite the presence of oncogenic Ras (40) . In light of our results, it Accordingly, recent studies indicate that treatment with a MEK inhibitor alongside an EGFR inhibitor synergistically inhibits the growth of cancer cells harboring oncogenic KRAS mutations (29, 49) . Taken together, these studies are consistent with our findings and suggest that targeting the MAPK pathway in combination with the appropriate RTK is potentially beneficial as well as necessary to effectively treat cancers harboring oncogenic RAS mutations. Importantly, this approach would concurrently block the RTK-mediated activation of wild-type Ras signaling while suppressing the basal levels of MAPK signaling sustained by oncogenic Ras.
METHODS

Cell Culture
The T24 cell line was kindly provided by Dr. Osamu Tetsu (UCSF); all other cell lines were obtained from the American Type Culture Collection. No additional cell line authentication was conducted by the authors. Cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FBS and incubated at 37°C in a 5% CO 2 incubator. For stable cell line generation, genes were cloned into pENTR or pDONR 221 vectors (Invitrogen), transferred into a Gateway-compatible derivative of the pFBNeo retroviral vector using recombination mediated Gateway technology (Invitrogen), and were transduced into HBL100 cells using retrovirus. All Ras constructs are of human origin and have been described previously (2) .
Cell stimulation and drug treatments
For stimulation with recombinant EGF (Invitrogen), cells were serum-starved overnight prior to 
Young, et al. 17 acute stimulation with 30 ng/ml EGF for 5 minutes, unless otherwise noted. For analysis of cellular signaling post U0126 or erlotinib treatment, cells were serum-starved overnight and pretreated with either 10 μm of drug or vehicle control (DMSO) for 1 hour prior to acute stimulation with EGF.
RNA Interference
Cells were transfected with 80 nM siRNA (Qiagen) using Lipofectamine RNAiMAX 
Immunoblot Analysis
Cells were washed twice in ice cold PBS and lysed in 1% Triton lysis buffer (25 mM Tris pH 7.5, 150 mM NaCl, 1% Triton X-100, 1 mM EDTA, 1 mM EGTA, 20 mM NaF, 1 mM Na 2 VO 4 , and 1 mM DTT) supplemented with a protease inhibitor cocktail (Roche) and cleared by centrifugation. Protein concentrations were determined by the Bio-Rad Protein Assay (Bio-Rad).
Equal amounts of protein extracts were resolved using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (NuPAGE, Invitrogen), transferred to a nitrocellulose membrane, and 
Ras-GTP Assay
Cells were washed twice in ice cold PBS and lysed in 1% TX100-TNM lysis buffer (20 mM Tris pH 7.5, 5 mM MgCl 2 , 150 mM NaCl,1% Triton-X100) supplemented with 1 mM DTT, protease and phosphatase inhibitors (Sigma), and were processed as described above. Equal amounts of protein from each sample were added to 10 ȝl of packed GST-Raf-RBD beads in 300-500 ȝl of 1% TX100-TNM lysis buffer and rotated at 4°C for 1-2 hours. Beads were washed three times with 1 ml of cold lysis buffer and boiled in LDS sample buffer (Invitrogen).
Cell Proliferation Analysis
Forty-eight hours after siRNA transfection, cells were trypsinized and seeded at equal densities in 12-well plates in triplicate for cell proliferation analysis. Samples were collected immediately at the time of seeding, and were harvested at 24 hour intervals thereafter as indicated. Accurate cell counts were obtained using a Coulter particle analyser.
Erlotinib Growth Inhibition Assay
Twenty-four hours after siRNA transfection, cells were trypsinized and seeded in 96-well plates at 3500 cells per well. The following day, cells were treated with a serial dilution of erlotinib (six replicates per drug concentration) and allowed to proliferate for an additional 72 hours. Cell proliferation was measured using CyQUANT Direct Cell Proliferation Assay (Life Technologies). For each siRNA condition, data are expressed as the fraction of maximal cell growth at 72 hours post erlotinib treatment and dose-response curves were generated using GraphPad Prism software. All assays were performed at least three independent times and representative curves are shown. 
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